BioCentury

8:00 AM GMT, Dec 19, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Status

Revlimid lenalidomide: Phase III started

Celgene and Groupe d'Etude des Lymphomes de l'Adulte (GELA) began the open-label, international Phase III RELEVANCE trial to compare

Read the full 190 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.